NAV-242 / Sera Medicines - LARVOL DELTA

Preclinical Characterization of NAV-242, a half-life extended bispecific antibody against TNF-alpha and OX40L (AAD 2026) - "NAV-240 is a tetravalent bispecific antibody designed to address this unmet need by blocking both TNF-α and OX40L. Enhanced stability and in vivo PK were achieved upon generation of NAV-242, a potential best-in-class therapeutic for autoimmune conditions like hidradenitis suppurativa. Clinical studies with NAV-242 are scheduled to initiate in 2026."

Bispecific • Preclinical • Hidradenitis Suppurativa • Immunology • Inflammation • TNFA • TNFSF4

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in adults with Hidradenitis Suppurativa. (ANZCTR) - P1 | N=6 | Not yet recruiting | Sponsor: Navigator Medicines

New P1 trial • Dermatology • Hidradenitis Suppurativa • Immunology

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in Healthy Adults. (ANZCTR) - P1 | N=48 | Not yet recruiting | Sponsor: Navigator Medicines

New P1 trial • Immunology

FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026 (The Manila Times) - "HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1 Program with Ph1a Dosing to Begin in Q1 2026...SAD results are expected in 4Q2026....Navigator Medicines is expanding its rights to NAV-240 and NAV-242 outside of Korea to now include China, providing the company with broadened clinical development and commercialization opportunities."

Commercial • First-in-human • New P1 trial • New P2a trial • Crohn's disease • Hidradenitis Suppurativa